The design of the mortality assessment in congestive heart failure trial (MACH-1, mibefradil)

Clinical Cardiology

Volumn 20, Issue 4, 1997, Pages 320-326

  Barry Levine, T ^a  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

heart failure; mibefradil; survival; T channel calcium blocker

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; ENDOTHELIN; MIBEFRADIL; NORADRENALIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORGANIZATION; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SURVIVAL;

EID: 1842338029     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960200404     Document Type: Article

References (33)

1. U.S. Dept of Health and Human Services. NHLBI report of the task force on research in heart failure. PHS-NIH 1994; Springfield, Va. 22161
2. Schocken DD, Arrieta MI, Leaverton PE: Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Curdiol 1992;20:301-306
3. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971;285:1440-1446
4. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435
5. Cohn JN, Johnson G, Ziesche S, Fletcher RD, Doherty JU, Hughes CV, Carson P, Contion G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J. Rouleau JL, Rutherford JD, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327':669-677
7. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828
8. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691
9. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
10. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schlapp B, Tudor R, Hefti F, Schmitt R, Egers H: Ro 40-5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991 ;9:4-17
11. 2+ channel by Ro 40-5967. Circulation Res 1994;75:144-148
12. 2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4:731-736
13. Veniant M, Clozel JP, Wolfgang R: Ro 40-5967. in contrast to diltiazem. does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pliannacol 1991;17:272-284
14. Bakx LM, van der Wall EE, Braun S. Emanuelsson H, Bruschke AVG. Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter. placebo-controlled study. Am Heart J 1995;130:748-757
15. Braun S, van der Wall EE, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro-40-5967), on silent ischemia in patients with chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 27:317-322
16. Rector TS, Cohn JN: Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-1025
17. Lan S, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrica 1983;70:659-663
18. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28:522-529
19. Bkaily G, Sculptoreau A, Jacques D, Economos D, Mernard D: Apamin. a highly potent fetal L-type Ca2+ current blocker in single heart cells. Am J Physiol 1992;262:463-471
20. Balke CW, Rose WC, Marban E, Wier WG: Macroscopic and unitary properties of physiological ion flux through T-type Ca2+ channels in guinea pig hearts. J Physiol (Lond) 1992;546:247-265
21. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993;73:777-782
22. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994;75:149-155
23. Xu X, Best PM: Increase in T-type calcium current in atriai myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci USA 1990;87:4655-4659
24. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am J Physiol 1993;265:C1239-1246
25. Furukawa T, Ito H, Niita J, Tsujino M, Adachi S, Hiroe M, Marumo F, Sawanobori T, Hiraoka M: Endothelin-1 enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes. Circ Res 1992;71:1242-1253
26. McCarthy RT, Isales C, Rasmussen H: T-type calcium channels in adrenal glomerulosa cells: GTP-dependent modulation by angiotensin II. Proc Natl Acad Sci USA 1993;90:3260-3264
27. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ: Tissuespecific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-482
28. Colucci WS: Myocardial cndothelin: Does it play a role in myocardial failure? Circulation 1996;93:1069-1072
29. Schmitt R, Clozel J-P, Iberg N, Buhler FR: Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscl Thromb Vase Biol 1995;15:1161-1165
30. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R, for the DiDi Study Group: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Circulation 1996;94:346-352
31. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Beuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114
32. Packer M: Calcium channel blockers in chronic heart failure: The risks of "physiologically rational" therapy. Circulation 1990;82: 2254-2257
33. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group: Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure; Results of V-HeFT III. Circulation 1995;92(suppl I):l-143